Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
- 21 January 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (3) , 190-195
- https://doi.org/10.1056/nejm199901213400304
Abstract
The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1–receptor antagonist would be an antiemetic in patients receiving anticancer chemotherapy.Keywords
This publication has 31 references indexed in Scilit:
- Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsNeuropharmacology, 1996
- Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesisClinical Therapeutics, 1996
- Quality of Life Studies in Chemotherapy-Induced EmesisOncology, 1996
- Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after CisplatinOncology, 1996
- Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group StudyOncology, 1994
- Delayed emesis following high-dose cisplatin: A double-blind randomised comparative trial of ondansetron (GR 38032F) versus placeboEuropean Journal Of Cancer, 1993
- Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesisThe Lancet, 1992
- Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesisClinical Oncology, 1990
- Neuropharmacology of Chemotherapy-induced EmesisDrugs, 1983
- Emesis as a Critical Problem in ChemotherapyNew England Journal of Medicine, 1981